According to the analysis, in 2023, Johnson & Johnson, Roche, Merck, Pfizer, AbbVie, Sanofi, Astrazeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline and other pharmaceutical companies have the largest revenue. They are 85.16 billion dollars, 65.32 billion dollars, 60.1 billion dollars, 58.5 billion dollars, 54.3 billion dollars, 46.6 billion dollars, 45.81 billion dollars, 45.44 billion dollars, 45 billion dollars, and 38.4 billion dollars, respectively. The industry said that in addition to the revenue performance of these pharmaceutical companies, their research and development progress is also worthy of attention.
Among them, since this year, Johnson & Johnson has made a number of research and development progress. For example, in January, Johnson & Johnson acquired several clinical antibody coupling drugs (ADCs) through the acquisition of Ambrx Biopharma. In March, its Tryvio oral tablet, developed jointly with Idorsia, was approved by the U.S. Food and Drug Administration (FDA) for use in combination with other antihypertensive drugs in adults with hypertension. In April, the FDA approved Carvykt i, a chimeric antigen receptor CAR-T therapy jointly developed with Legendary Biology, for the second-line treatment of adult patients with recurrent or refractory multiple myeloma.
Roche’s research and development progress is also noteworthy, with data showing that the company has a total of 146 clinical research projects including 82 new molecular entities (NME). Roche is also focusing on pipeline development in the fields of neuroscience, ophthalmology and immunology. In addition, in February, Xolair, a monoantibody jointly developed by Roche and Novartis, was approved by the FDA to reduce IGE-mediated food allergic reactions, including anaphylactic shock, that can occur in adults and children over 1 year of age due to accidental exposure to one or more foods, according to the review. In February, Roche’s covalizumab targeting complement protein C5 was approved by the China National Drug Administration for the treatment of paroxysmal sleep hemoglobinuria (PNH).
As for Merck, the company is gradually making up for its shortcomings in the hot ADC field. At present, the company has two ADC drugs entering phase III clinical trials. In terms of tumor vaccines, Merck has also begun to make efforts, and currently, its mRNA vaccine V940, which is jointly developed with Moderna, has also advanced to phase 3. The company has also made progress in more new mechanism drugs, such as the clinical development of MK-3543, an LSD1 inhibitor with Merck layout, and K drugs, has also surfaced. According to Merck’s plan, the company will also launch additional Phase 3 trials in 2024 to further increase the depth and breadth of the pipeline. In March, Merck’s Winrevair received FDA approval for the treatment of pulmonary arterial hypertension (PAH).
For Pfizer, inflammation and immunity are important strategic areas for the company’s current and future global footprint. In April this year, Pfizer announced the top line analysis of its pivotal Phase III respiratory syncytial virus (RSV) vaccine Abrysvo(RSVpreF) reached the primary endpoint. In addition, Pfizer received two FDA approvals in late April, including full approval of Pfizer’s TIVDAK product, which will be used to treat recurrent or metastatic cervical cancer. Another important FDA approval for Pfizer is the BEQVEZ product, a one-time gene therapy for adults with hemophilia b.
AbbVie has made new progress in research and development since this year, and now in May, the Upadacitinib tablets submitted by AbbVie (AbbVie) were proposed to be included in the breakthrough treatment variety by the Drug Evaluation Center (CDE) of the China National Drug Administration, and are intended to be used to treat adolescents and adults aged 12 and above with non-segmental vitiligo. In March, AbbVie acquired ImmunoGen’s ADC drug Elahere, which is fully approved by the U.S. FDA for the treatment of folate receptor alpha (FRα) -positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. In February, AbbVie’s Complementary biologics License Application (sBLA) for Epkinly, a CD20/ CD3-targeted bisspecific antibody developed in collaboration with Genmab for the treatment of adult patients with R/R follicular lymphoma (FL), was accepted by the US FDA and granted priority review status.
In addition, Astrazeneca has also made positive progress in several research and development projects this year, such as the company and Daiichi Sankyo (Daiichi Sankyo) joint development of the blockbuster antibody conjugate (ADC) drug Enhertu was approved by the U.S. FDA for the treatment of unresectable or metastatic HER2-positive solid tumors in adult patients. Voydeya, a small oral molecule, is approved by the US FDA for the treatment of paroxysmal sleep hemoglobinuria (PNH) patients.
Disclaimer: In no event does the information or opinions expressed herein constitute investment advice to anyone.
The article links: pharmaceutical https://www.zyzhan.com/news/detail/92973.html
About us
Wisdomdrugs Co., LTD., founded in September 2011, is headquartered in Changzhou Hang Seng Science and Technology Industrial Park. Today, the company’s R&D center is engaged in the process research and development, production, optimization, custom synthesis and technology transfer of API or pharmaceutical intermediates, plant extracts, compounds from laboratory scale to commercial scaleup production, to meet the growing requirements of customers.
The company focuses on the protection of intellectual property rights, continuous invention and innovation research and development of production processes, to avoid the regulatory market patent and intellectual property issues, perfect impurity research, to provide customers with a full set of CMC or DMF registration documents.
